Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications.
about
Knocking down disease: a progress report on siRNA therapeuticsNucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges.Long non-coding RNAs in cancer and development: where do we go from here?Prospects for Therapeutic Targeting of MicroRNAs in Human Immunological Diseases.DNA and RNA derivatives to optimize distribution and deliveryIntercalation-mediated nucleic acid nanoparticles for siRNA delivery.Combinatorial optimization of PEG architecture and hydrophobic content improves ternary siRNA polyplex stability, pharmacokinetics, and potency in vivo.Correction of a genetic deficiency in pantothenate kinase 1 using phosphopantothenate replacement therapy.Structure and decoy-mediated inhibition of the SOX18/Prox1-DNA interactionThe delivery of therapeutic oligonucleotidesCellular uptake and intracellular trafficking of oligonucleotidesCationic PTD/CPP-mediated macromolecular delivery: charging into the cell.Prospects for the development of epigenetic drugs for CNS conditions.Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis.Oligonucleotide therapeutics: chemistry, delivery and clinical progress.High-Yield Synthesis of Monomeric LMWP(CPP)-siRNA Covalent Conjugate for Effective Cytosolic Delivery of siRNA.Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.Lipophilic 2'-O-Acetal Ester RNAs: Synthesis, Thermal Duplex Stability, Nuclease Resistance, Cellular Uptake, and siRNA Activity after Spontaneous Naked Delivery.Stacking up CRISPR against RNAi for therapeutic gene inhibition.Reduction-Responsive Guanine Incorporated into G-Quadruplex-Forming DNA.Synthetic Nucleic Acid Analogues in Gene Therapy: An Update for Peptide-Oligonucleotide Conjugates.Therapeutic RNAi robed with ionic liquid moieties as a simple, scalable prodrug platform for treating skin disease.How to Tackle the Challenge of siRNA Delivery with Sequence-Defined Oligoamino Amides.Synthesis and Conjugation of Small Interfering Ribonucleic Neutral SiRNNs.Controlled in-cell activation of RNA therapeutics using bond-cleaving bio-orthogonal chemistry.Induction of RNAi Responses by Short Left-Handed Hairpin RNAi Triggers.CRISPR Genome Engineering for Human Pluripotent Stem Cell Research.Amide linkages mimic phosphates in RNA interactions with proteins and are well tolerated in the guide strand of short interfering RNAs.A versatile post-synthetic method on a solid support for the synthesis of RNA containing reduction-responsive modifications.Stimuli-responsive oligonucleotides in prodrug-based approaches for gene silencing.Worth the RISC?Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.Non-Nucleosidic Analogues of Polyaminonucleosides and Their Influence on Thermodynamic Properties of Derived Oligonucleotides.
P2860
Q28082939-47E9CE81-DA21-4C8E-822D-7BE8EA414763Q28085200-54BCB3CB-FA90-4A36-B6BF-0390EF1A5648Q35016600-B2863879-96A1-4A92-BE3E-F9EC11CB01C3Q35619546-AC9B6947-B514-4F07-8D64-4A8DCBB6B52CQ35858691-B9B536ED-F96D-4D38-B4F8-DC88180564AFQ36155481-84F9421F-138D-4BF2-B15C-4CCAD743C852Q36331202-9762F0C7-857B-4231-A13F-0BBA3EACAAEDQ36608623-19801A96-1EE7-465A-BDE8-3A905751D15CQ36870509-CBF40832-29C1-4347-AE95-C8481C41B2ABQ37210936-5969581D-7BAA-4CAC-9774-BF0176F10062Q38424377-F7DA0DA3-1500-4B95-951A-EDCB333C767DQ38494545-8BD9C2B4-DEDD-48A2-950F-219ED4CFC46AQ38497844-40121165-CD85-40E1-93FF-8D6FE3CB47FAQ38575287-CDA3E944-30F2-473A-A978-99C1F7E772BDQ38618638-9CB39739-6F1C-4EC7-87C6-830393039838Q38651811-B14522C5-4FA8-46E1-84AF-56CEC2833088Q38656763-0F03656E-D202-4F13-9E62-2982FA672649Q38734379-8D16262A-0A5E-4AB2-82A7-978EAABB1BDCQ38811165-776514CE-105D-482A-A901-081EC074BF03Q38819883-9D6896BC-BDA1-4A0A-96BB-6636149CEC12Q39373677-F2874C66-C73D-41E7-8F6B-1DA6BAD722F6Q39406180-030B719B-721E-4435-883C-5E5CDF37CAD2Q40689442-620B6478-DF7D-4B4C-BC7D-4E2EB31013E6Q41502531-8F0735D3-1654-40A2-985C-D4C610A8C000Q42367277-F0712ED4-2378-4622-BA1A-EC9ED3A7BC3EQ46118467-AC1C4CA1-148D-470D-8DE2-901365723F30Q46522290-2CF974D2-CA8E-4339-BBC6-AFC6B39A152AQ47222077-7334600E-58F2-476D-A94E-E8EC82E8A6C0Q50791038-3F2476DF-6041-4A2D-9FEF-92636F969830Q51742560-AD83701B-A4A0-43AE-B7E0-8B6F218E7355Q52711221-2A17809C-49A2-4414-8270-F7341C0E38ACQ53631590-435DE029-24E3-4F8E-9D61-5EE0589CD796Q53831643-7C238B07-9475-4F4C-B330-597B5DAF8E47
P2860
Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficient delivery of RNAi pro ...... iester backbone modifications.
@ast
Efficient delivery of RNAi pro ...... iester backbone modifications.
@en
type
label
Efficient delivery of RNAi pro ...... iester backbone modifications.
@ast
Efficient delivery of RNAi pro ...... iester backbone modifications.
@en
prefLabel
Efficient delivery of RNAi pro ...... iester backbone modifications.
@ast
Efficient delivery of RNAi pro ...... iester backbone modifications.
@en
P2093
P2860
P356
P1433
P1476
Efficient delivery of RNAi pro ...... riester backbone modifications
@en
P2093
Aaron D Springer
Akiko Eguchi
Alexander S Hamil
Apollo D Kacsinta
Arjen van den Berg
Asaf Presente
Bryan R Meade
Caroline Palm-Apergi
Connor F Dowdy
Edwige Gros
P2860
P2888
P304
P356
10.1038/NBT.3078
P577
2014-11-17T00:00:00Z